Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma

Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma

Share This Post

March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL) in patients who have had two or more lines of systemic therapy.

The effectiveness of the medication was assessed in Study BGB-3111-212 (ROSEWOOD; NCT03332017), which was a clinical trial including 217 adult patients with relapsed or refractory follicular lymphoma (FL) who had undergone at least 2 previous systemic therapies. The experiment was conducted at many centers and was open-label and randomized. The patients were randomly assigned in a ratio of 2:1 to receive either zanubrutinib at a dose of 160 mg orally twice daily until the disease progresses or there is unacceptable toxicity, in combination with obinutuzumab (ZO), or to receive obinutuzumab alone. The median number of previous treatment attempts was 3, with a range of 2 to 11.

The effectiveness of the treatment was assessed by an independent review committee, based on the overall response rate (ORR) and the duration of response (DOR). The overall response rate (ORR) was 69% (95% confidence interval [CI]: 61, 76) in the ZO arm and 46% (95% CI: 34, 58) in the obinutuzumab arm (two-sided p-value, 0.0012). After 19.0 months of observation, the median duration of response (DOR) was not determined in the ZO arm (95% CI: 25.3 months, NE), while it was 14.0 months (95% CI: 9.2, 25.1) for patients who received obinutuzumab monotherapy. In the ZO arm, the estimated rate of durable objective response (DOR) at 18 months was 69% with a 95% confidence interval (CI) of 58% to 78%.

In clinical studies of zanubrutinib, the most frequently seen negative effects (occurring in at least 30% of cases), which also include abnormal laboratory results, were reduced levels of neutrophils (51%) and platelets (41%), upper respiratory tract infections (38%), bleeding (32%), and musculoskeletal discomfort (31%). ZO caused serious adverse effects in 35% of patients with FL.

The suggested zanubrutinib dose is 160 mg administered orally twice day or 320 mg administered orally once daily unless there is disease progression or intolerable toxicity.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy